Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Viking Therapeutics has seen a significant drop, despite positive news and promising GLP-1 drug developments. Find out why ...

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised Bagsværd ...

Over 137 million U.S. adults qualify for semaglutide Semaglutide shows promise for treating multiple conditions, beyond obesity and diabetes The cost of semaglutide remains a significant barrier ...

Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...

And the inaugural ESSENCE Black Women in Business Dinner was a testament to the exceptional achievements of Black women across various industries. Hosted at the Four Seasons New Orleans ...

“This study demonstrated that at maximum tolerated dose tirzepatide (10 mg or 15 mg) was superior to maximum tolerated semaglutide (1.7 mg or 2.4 mg) in a head-to-head trial,” says Dr. Sean ...

Zepbound ® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide ... five key secondary endpoints in this trial of adults living with obesity or overweight ...